Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
12/2003
12/24/2003CN1462630A Medicine for treating osteoporosis and its preparation method
12/24/2003CN1462628A Pasting medicated plaster for treating bone disease
12/24/2003CN1131865C 作为选择性COX－2抑制剂的取代的咪唑并[1,2a]吖嗪 Substituted imidazole as selective COX-2 inhibitors and [1,2a] azines
12/24/2003CA2489870A1 Low molecular weight oversulfated polysaccharide
12/24/2003CA2489866A1 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
12/24/2003CA2489447A1 Novel hexahydro-pyridazine-3-carbocylic acid hydrazide or hydrazone derivatives, combinatorial libraries containing same, use thereof as medicines, pharmaceutical compositions containing same and methods for preparing same
12/24/2003CA2489182A1 N-bridged selective androgen receptor modulators and methods of use thereof
12/24/2003CA2489106A1 Film-shaped mucoadhesive administration form for administering cannabis active ingredients
12/24/2003CA2489098A1 Bazedoxifene treatment regimens
12/24/2003CA2488708A1 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier
12/24/2003CA2488117A1 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
12/24/2003CA2487948A1 Azole methylidene cyanide derivatives and their use as protein kinase modulators
12/24/2003CA2485346A1 Human adam-10 inhibitors
12/24/2003CA2485090A1 Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates (no-bisphosphonate)
12/23/2003US6667334 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
12/23/2003US6667331 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
12/23/2003US6667325 P38MAP kinase inhibiters; tumor necrosis factor alpha, interleukin 1 and 6 and cyclooxygenase II related diseases
12/23/2003US6667320 For therapy of infalmmation; asthma, cancer, arthritis, multiple sclerosis; prophylaxis of infection of target cells by a human immunodeficiency virus (HIV)
12/23/2003US6667318 LFA-1 antagonist compounds
12/23/2003US6667316 Pharmaceutically active isoindoline derivatives
12/23/2003US6667300 Purinyl substituted quinazoline-4-one derivatives
12/23/2003US6667298 26,27-Homologated-20-EPI-2-alkyl-19-NOR-vitamin D compounds
12/23/2003CA2149207C Compounds that inhibit t cell proliferation and methods using the same
12/18/2003WO2003104807A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
12/18/2003WO2003104485A2 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
12/18/2003WO2003104473A2 Galactosyl isomalt, method for production and use thereof
12/18/2003WO2003104459A1 Fcyriia transgenic animal model for autoimmune disease
12/18/2003WO2003104407A2 T cell receptor cdr3 sequences and methods for detection
12/18/2003WO2003104260A2 Pharmaceutical formulation
12/18/2003WO2003104253A2 9-alpha-substituted estratrienes as selectively active estrogen
12/18/2003WO2003104235A1 Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]pyrazines and decahydropyrazino[1,2-a]azepines
12/18/2003WO2003104230A1 Bicyclic pyrimidine derivatives
12/18/2003WO2003104229A1 Novel fused imidazole derivative
12/18/2003WO2003104226A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
12/18/2003WO2003104225A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
12/18/2003WO2003104223A1 Pyrazole-derivatives as p38 kinase inhibitors
12/18/2003WO2003104222A1 Bisindolyl-maleimid derivatives as kinase inhibitors
12/18/2003WO2003104219A1 Nf-kb inhibitors
12/18/2003WO2003104218A1 Nf-:b inhibitors
12/18/2003WO2003104205A1 Aryloximes
12/18/2003WO2003104204A1 Pyridazine derivatives
12/18/2003WO2003104203A1 Therapeutic molecules and methods-1
12/18/2003WO2003104195A1 4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
12/18/2003WO2003103772A1 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
12/18/2003WO2003103734A1 Strontium-apatite-cement-preparations and the use thereof
12/18/2003WO2003103710A1 Combined effects of therapeutic or preventive agent composition for bone breakage
12/18/2003WO2003103709A2 Modulation of bone development
12/18/2003WO2003103703A1 Remedy for bone mtabolic diseases
12/18/2003WO2003103694A1 Use of active ingredient mixtures containing tocopherols and extracts of harpagopytum procumbens for producing a medicament for arthritis
12/18/2003WO2003103687A1 Liquid formulation of decitabine and use of the same
12/18/2003WO2003103684A1 Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
12/18/2003WO2003103682A1 Compositions for cancer therapy saponins or sapogenins
12/18/2003WO2003103681A2 Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow oedema
12/18/2003WO2003103677A1 Derivatives of azepine and thiazeran as interleukin converting enzyme inhibitors
12/18/2003WO2003103671A1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
12/18/2003WO2003103664A1 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
12/18/2003WO2003103661A1 SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
12/18/2003WO2003103658A1 Immunity-related protein kinase inhibitors
12/18/2003WO2003103604A2 Gamma lactams as prostaglandin agonists and use thereof
12/18/2003WO2003103590A2 (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
12/18/2003WO2003103585A2 Methods of treating angiogenesis, tumor growth, and metastasis
12/18/2003WO2003103583A2 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
12/18/2003WO2003103575A2 Compounds, compositions, and methods
12/18/2003WO2003103574A2 Protease inhibitors
12/18/2003WO2003103478A2 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs
12/18/2003WO2003097052A3 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
12/18/2003WO2003087087A3 Heterocyclic compounds and their use as modulators of p38 map kinase
12/18/2003WO2003082302A3 Bioadhesive directed somatic cell therapy
12/18/2003WO2003079991A3 Method for administration of growth hormone via pulmonary delivery
12/18/2003WO2003074500A3 N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
12/18/2003WO2003066630A3 Quinolinone derivatives for treating cell proliferation related disorders
12/18/2003WO2003066593A3 Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl )-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-methyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections
12/18/2003WO2003057149A3 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
12/18/2003WO2003051917A3 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
12/18/2003WO2003050108A8 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
12/18/2003WO2003045363A3 Treatment of th2 dominated immunological disease states with progesterone receptor antagonists
12/18/2003WO2003045362A3 Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
12/18/2003WO2003044021A3 Substituted indolizine-like compounds and methods of use
12/18/2003WO2003042405A3 Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
12/18/2003WO2003030885A3 Modulation of the adventitial tool-like receptor
12/18/2003WO2003029437A3 Secreted proteins
12/18/2003WO2003028712A3 Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
12/18/2003WO2003027234A3 Small organic molecule regulators of cell proliferation
12/18/2003WO2003026692A3 Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex
12/18/2003WO2003025149A3 Cell populations which co-express cd49c and cd90
12/18/2003WO2003000864A8 Nucleic acid-associated proteins
12/18/2003WO2002100899A3 Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
12/18/2003WO2002092781A3 Peptide compounds for counteracting reactive oxygen species and free radicals
12/18/2003WO2002081668A3 Desaturase genes and uses thereof
12/18/2003WO2002081627A3 Methods of screening and using inhibitors of angiogenesis
12/18/2003WO2002062398A3 Radioactively labelled conjugates of phosphonates
12/18/2003WO2002038561A8 Indolylmaleimide derivatives as protein kinase c inhibitors
12/18/2003WO2002017878A8 Lung surfactant compositions with dynamic swelling behaviour
12/18/2003WO2002014536A9 Odulating multiple lineage kinase proteins
12/18/2003WO2001091734A8 Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases
12/18/2003US20030232986 Inhibitors of caspases
12/18/2003US20030232944 Applying to the tissue formulation comprising first precursor component second precursor component comprises electrophilic component which crosslink at physiological temperatures over a period of time following application
12/18/2003US20030232889 For therapy of cancer, restenosis, psoriasis, autoimmune disease, atherosclerosis, osteoarthritis, rheumatoid arthritis, heart failure, chronic pain, and neuropathic pain
12/18/2003US20030232877 1,3-Bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
12/18/2003US20030232869 N3 alkylated benzimidazole derivatives as MEK inhibitors
1 ... 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 ... 820